α4CB-1.1 / Trigone Pharma, 4C Biomed - LARVOL DELTA

Anti-4CB1: A Novel Selective HVEM-Blocking Antibody Enhancing T-Cell and Macrophage Immunity Against Solid Tumors. (PubMed, Mol Cancer Ther) - "Anti-4CB1 enhances both adaptive and innate anti-tumor immunity and shows activity in anti-PD1 resistant settings. These findings support its potential as a novel therapeutic agent and suggest HVEM as a predictive biomarker for immunotherapy response."

IO biomarker • Journal • Oncology • Solid Tumor • BTLA • IFNG • LAMP1 • TNFA

Data on Anti-4CB1 Published in Molecular Cancer Therapeutics Journal (The Manila Times) - "Action in real patient tumors in different cancer types: Using 49 freshly collected patient tumor samples spanning multiple cancer types, Anti-4CB1 boosted tumor-cell killing in 28.5% of cases, compared with 14.3% for anti-PD1 alone. The headline finding was that nine of the responding samples responded to Anti-4CB1 but not to anti-PD1. Activity was strongest in melanoma, colon, ovarian and renal cancers."

Preclinical • Colon Cancer • Melanoma • Ovarian Cancer • Renal Cell Carcinoma

Trigone Pharma Announces a Strategic Collaboration with 4C Biomed to Develop a Novel Treatment for High-Grade Bladder Cancer (GlobeNewswire) - "Trigone Pharma...announced a collaboration with 4C Biomed, to develop an innovative treatment for bladder cancer. The collaboration will focus on local administration of 4C Biomed’s anti 4CB-1 as an innovative treatment for high-grade non-muscle invasive bladder cancer....The approach involves the local delivery of 4C Biomed’s first-in-class monoclonal antibody that targets HVEM (TNFRSF14) - a novel Immunotherapy, using Trigone’s proprietary technology to increase dwell time - which has been shown to significantly improve the effectiveness of bladder targeted therapies."

Licensing / partnership • Bladder Cancer • Genito-urinary Cancer • Oncology • Urothelial Cancer